Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients
Marner, B. ; Agner, T. ; Binder, C. ; Lernmark, Å LU
; Nerup, J.
LU
; Mandrup-Poulsen, T.
and Walldorff, S.
(1985)
In Diabetologia
28(12).
p.875-880
- Abstract
A cohort of 82 patients with Type 1 (insulin-dependent) diabetes was followed prospectively for 24 months, and 54 of them for 30 months, to study the relationship between fasting levels of immunoreactive C-peptide and titres of islet cell antibodies. After diagnosis, fasting C-peptide rose temporarily for 1-6 months of insulin therapy and declined continuously thereafter. While islet cell antibodies were present among 55% of the newly diagnosed patients, only 31% remained positive at 30 months. Their antibody titres decreased from 1:81 at diagnosis to 1:3. Only 3 patients (4%) who were islet cell antibody negative at diagnosis became positive later. The median C-peptide values among the persistently islet cell antibody positive patients... (More)
A cohort of 82 patients with Type 1 (insulin-dependent) diabetes was followed prospectively for 24 months, and 54 of them for 30 months, to study the relationship between fasting levels of immunoreactive C-peptide and titres of islet cell antibodies. After diagnosis, fasting C-peptide rose temporarily for 1-6 months of insulin therapy and declined continuously thereafter. While islet cell antibodies were present among 55% of the newly diagnosed patients, only 31% remained positive at 30 months. Their antibody titres decreased from 1:81 at diagnosis to 1:3. Only 3 patients (4%) who were islet cell antibody negative at diagnosis became positive later. The median C-peptide values among the persistently islet cell antibody positive patients decreased from 0.11 pmol/ml at 18 months, to 0.09 pmol/ml at 24 months, to 0.06 pmol/ml at 30 months compared to 0.18 (p=0.04), 0.15 (p=0.05) and 0.16 (p< 0.003) pmol/ml, respectively, for the islet cell antibody negative patients. The median slope for the latter was -0.09 compared to -0.19 for the islet cell antibody positive patients (p=0.01). These differences were reflected in increasing dosages of insulin, since patients remaining antibody-positive for 30 months were given 1.3-1.4 times more insulin (p=0.01-0.004) than the antibody negative patients. This study demonstrates that islet cell antibodies may be a useful marker for predicting an increased rate by which endogenous B cell function is lost in Type 1 diabetes.
(Less)
- author
- Marner, B.
; Agner, T.
; Binder, C.
; Lernmark, Å
LU
; Nerup, J.
LU
; Mandrup-Poulsen, T.
and Walldorff, S.
- publishing date
- 1985-12-01
- type
- Contribution to journal
- publication status
- published
- keywords
- fasting blood sugar, fasting C-peptide, insulin dosage, islet cell antibodies, prospective analysis, Type 1 (insulin-dependent) diabetes
- in
- Diabetologia
- volume
- 28
- issue
- 12
- pages
- 6 pages
- publisher
- Springer
- external identifiers
-
- pmid:3912242
- scopus:0022296677
- ISSN
- 0012-186X
- DOI
- 10.1007/BF00703129
- language
- English
- LU publication?
- no
- id
- 3a6352d3-afa8-4b55-ae58-3563c369b992
- date added to LUP
- 2019-09-16 12:36:25
- date last changed
- 2024-03-25 07:51:43
@article{3a6352d3-afa8-4b55-ae58-3563c369b992,
abstract = {{<p>A cohort of 82 patients with Type 1 (insulin-dependent) diabetes was followed prospectively for 24 months, and 54 of them for 30 months, to study the relationship between fasting levels of immunoreactive C-peptide and titres of islet cell antibodies. After diagnosis, fasting C-peptide rose temporarily for 1-6 months of insulin therapy and declined continuously thereafter. While islet cell antibodies were present among 55% of the newly diagnosed patients, only 31% remained positive at 30 months. Their antibody titres decreased from 1:81 at diagnosis to 1:3. Only 3 patients (4%) who were islet cell antibody negative at diagnosis became positive later. The median C-peptide values among the persistently islet cell antibody positive patients decreased from 0.11 pmol/ml at 18 months, to 0.09 pmol/ml at 24 months, to 0.06 pmol/ml at 30 months compared to 0.18 (p=0.04), 0.15 (p=0.05) and 0.16 (p< 0.003) pmol/ml, respectively, for the islet cell antibody negative patients. The median slope for the latter was -0.09 compared to -0.19 for the islet cell antibody positive patients (p=0.01). These differences were reflected in increasing dosages of insulin, since patients remaining antibody-positive for 30 months were given 1.3-1.4 times more insulin (p=0.01-0.004) than the antibody negative patients. This study demonstrates that islet cell antibodies may be a useful marker for predicting an increased rate by which endogenous B cell function is lost in Type 1 diabetes.</p>}},
author = {{Marner, B. and Agner, T. and Binder, C. and Lernmark, Å and Nerup, J. and Mandrup-Poulsen, T. and Walldorff, S.}},
issn = {{0012-186X}},
keywords = {{fasting blood sugar; fasting C-peptide; insulin dosage; islet cell antibodies; prospective analysis; Type 1 (insulin-dependent) diabetes}},
language = {{eng}},
month = {{12}},
number = {{12}},
pages = {{875--880}},
publisher = {{Springer}},
series = {{Diabetologia}},
title = {{Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients}},
url = {{http://dx.doi.org/10.1007/BF00703129}},
doi = {{10.1007/BF00703129}},
volume = {{28}},
year = {{1985}},
}